The NICE threshold: How much is too much? Who decides?

By Ryan Li Feb. 19, 2015

Prof Karl Claxton, University of York, and colleagues have argued that NICE is advising the UK National Health Service “to pay too much” for new drugs. NICE typically recommends treatments for use in the NHS where their cost-effectiveness falls below the threshold of around £20,000 and £30,000 per QALY gained (quality-adjusted life year). New research led by Claxton suggests that paying more …